Tom3 schreef op 16 april 2021 10:47:
As with the solid tumor and pulmonary franchises, we view our ability to address
skeletal muscle as the sharp end of a spear. Once we achieve clinical proof of
concept, we expect to rapidly expand our pipeline into new indications and gene
targets addressable via muscle delivery. We remain on track to file a CTA by the
very end of 2020.
Nou ja 9 maanden vertraging is toch niet wat we gewend zijn. De cta is nu gepland in Q3.